

Who We Are

Background

Fertiga is a pioneering biotech spin-off from UZ Brussel & Vrije Universiteit Brussel and aims to transform assisted reproduction. Leveraging cutting-edge research, Fertiga introduces the **Aurora niPCT™**, a non-invasive clinically proven preimplantation diagnostic cumulus cell test that enhances IVF success by accurately identifying the most viable oocytes and embryos used at the first transfer.

Goal

We aim to make fertility treatments more effective, more accessible and less stressful for the patients. We want to help as many women as possible to achieve pregnancy on the first attempt.


Values

- **Make a difference** – advancing fertility treatment through science and innovation.
- **Empower patient success** – helping embryologists identify the most competent embryos.
- **Solve meaningful problems** – tackling physical, financial and emotional challenges.

Contact Us

info@fertiga.com

or



Aurora niPCT™

Oocyte Competence Evaluation

fertiga




Aurora niPCT™

Oocyte competence evaluation

Cumulus cells naturally surround and support the oocyte encoding the molecular signals of highest quality. The Aurora niPCT™ measures the oocyte's biological potential itself.

Statistically increased pregnancy and live birth rates

The results of our clinical study showed a significant increase in clinical pregnancy rate from 29% to 61% and an increase in live birth rate from 27% to 50% in the first transfer cycle*.



Study on ICSI patients (n=633) stimulated with HP-hMG and undergoing Day3 transfer.

* Van Vaerenbergh et al., 2021.

Principle

The Aurora niPCT™ is an innovative, non-invasive molecular test which analyses cumulus cells.

Unlike morphology-based assessments — it objectively measures. Unlike invasive genetic testing, it causes no harm. Unlike other emerging technologies, the Aurora niPCT™ is based on known genes and not a black box.

Cumulus cells are collected individually from all oocytes of a patient. Quantitative PCR is performed for expression analysis of specific predictive genes that allows ranking of the oocytes by their potential to develop into a baby.

High prediction power for live birth on Day5 embryo transfer

Gene expression analysis of cumulus cells from >2,000 oocytes allowed us to identify the competence of oocytes leading to live birth for patients stimulated with different hormones.

| Stimulation Protocol | Live birth prediction accuracy (PPV) |
|---|--------------------------------------|
| hMG (e.g. Menopur, Meriofert) | 80% (82%)* |
| rFSH (e.g. Gonal-f, Rekovelle, Puregon, Ovaleap, Bemfola) | 86% (92%)** |
| rFSH+rLH (Pergoveris) | 88% (83%)*** |

PPV - positive predictive value; * Van Vaerenbergh et al., 2021; ** novel, unpublished; *** Adriaenssens et al., 2025.

Choose Us To Achieve

Increased safety  non-invasive test

Proven 50%  live birth after SET in the first attempt

Reduced  time-to-pregnancy

Aurora niPCT™ can also be used for

- social oocyte freezing (Adriaenssens et al., 2024)
- donor cycles